RPL3 and cancer: Elicitation of such an effect involves RPL3-mediated negative regulation of two molecular targets in p53-null cells treated with 5-FU: (1) CBS (cystathionine-β-synthase), a factor enhancing energetics, proliferation, and migration of cancer cells and inflammation, and (2) NFҡB, a factor activated in many solid tumors linking cancer and inflammation.